Publish in this journal
Journal Information
Vol. 16. Issue 3.
Pages 249-250 (May - June 2020)
Share
Share
Download PDF
More article options
Vol. 16. Issue 3.
Pages 249-250 (May - June 2020)
Letter to the Editor
Full text access
Successful use of azathioprine in glucocorticoid refractory immune amegakaryocytic thrombocytopenia of lupus
El uso exitoso de azatioprina en la trombocitopenia amegacariocítica inmune glucocorticoide refractaria del lupus
Visits
...
Latika Guptaa, Vikas Guptaa,
Corresponding author
vikasgcapri@yahoo.co.in

Corresponding author.
, Krushna Chandra Panib, Navkirti Mittalc, Vikas Agarwala
a Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
b Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
c Department of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor:

Amegakaryocytic thrombocytopenia is a rare complication of systemic lupus erythematosus (SLE). Consequently, evidence for its treatment is limited to case reports.1–3 Here we report successful use of azathioprine in this setting.

A 48-year-old woman presented with polyarthralgia involving bilateral small and large joints, low-grade fever, and easy fatigability of eight years duration. She had Raynaud phenomenon but no skin rashes, oral ulcers, sicca symptoms or photosensitivity. The examination was unremarkable except for minor pedal edema.

For last two months, her creatinine had been elevated (3.3mg/dL). She had bland sub-nephrotic proteinuria and bilateral shrunken kidneys on sonography. She had been having intermittent thrombocytopenia in the past. Platelet count was 80,000/mm3 at her first presentation. She had never been worked up for lupus before, given the mild and intermittent nature of her arthralgia, and non-specific symptoms. Anti-nuclear antibody was positive by immunofluorescence in a speckled pattern. Anti-double-stranded DNA antibody was more than 300IU/mL, complement levels were normal and Direct Coombs test was negative. She was initiated on 0.25mg/kg prednisone and hydroxychloroquine with a diagnosis of systemic lupus erythematosus. She came back a week later with high-grade fever. This time she had thrombocytopenia of (10,000/mm3) and lymphopenia (300/mm3). The diagnostic possibilities considered were lupus disease activity, Macrophage Activation Syndrome (MAS) and viral fever. Serology for Dengue and Epstein–Barr virus were negative, as was polymerase chain reaction for Cytomegalovirus. Hemoglobin of 11.6g/dL, normal aspartate transaminase (16IU/L), alanine transaminase (21IU/L), and coagulation parameters made MAS unlikely. A bone marrow biopsy revealed reduced megakaryocytes with preserved erythroid and myeloid precursors, and plasma cell infiltrate in the interstitium. It ruled out myelophthisis from infiltrative disorders such as myelofibrosis, infections and neoplasia. She was not on any drug that could cause thrombocytopenia, nor had any evidence of exposure to toxins. Thus, with a background of lupus, she was diagnosed as having immune-mediated amegakaryocytic thrombocytopenia. Initially, she was administered intravenous methylprednisolone at a dose of 1g daily for three days and then, intravenous immunoglobulin at a dose of 1g/kg daily for two days. The platelet count rose to 80,000/mm3 over the next seven days, but the rise was ill sustained, necessitating the addition of another immunosuppressant. The literature on therapeutic options in this setting is limited to occasional reports of Cyclosporine, Rituximab, and Eltrombopag. Due to the presence of end-stage renal disease as well as cost considerations, azathioprine (AZA) was considered. The dose was gradually escalated from 25mg/day to 125mg/day. Platelet counts stabilized at >100,00/mm3 by two months. The patient has done well over 3 years after initiating AZA, without further thrombocytopenia or new organ involvement related to lupus.

It has been long believed that bone marrow aplasia in lupus is an exception rather than the rule.4 Recent series have described aplasia in 10–50% of biopsies from lupus patients, suggesting it may be more common than previously thought.5,6 In amegakaryocytic thrombocytopenia, the pathogenesis is believed to be immune-mediated. Antibodies to the thrombopoietin receptor (c-Mpl) can block signaling on megakaryocytes, thereby halting maturation of platelets in the bone marrow.7,8 T-cells in lupus have inhibitory effects on Colony forming unit-Monocyte (CFU-M).9 Change in T helper to suppressor cell ratio was one of the earliest cited reasons for impaired megakaryopoiesis.4 The infiltration of plasma cells in the bone marrow in our patient is surrogate for immune-mediated pathogenesis, though we haven’t substantiated this by the antibody or in vitro T cell assays.

Since there is evidence of a role of both cell-mediated and humoral factors in the pathogenesis of this entity in lupus, azathioprine may be a good choice when other therapies fail or cannot be used. In our knowledge, literature on the use of AZA in this setting is limited to a single case report.10 With successful treatment in our patient, we suggest that azathioprine should be added to the armamentarium to treat this rare entity.

Funding

None to report.

Conflict of interests

None to report.

References
[1]
T. Fukushima, L. Dong, T. Sakai, T. Sawaki, M. Miki, M. Tanaka, et al.
Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
Lupus, 17 (2008), pp. 210-214
[2]
I. Cela, I.J. Miller, R.S. Katz, A. Rizman, J.M. Shammo.
Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
Clin Adv Hematol Oncol, 8 (2010), pp. 806-809
[3]
A.G. Tristano.
Acquired amegakaryocytic thrombocytopenic purpura: review of a not very well-defined disorder.
Eur J Intern Med, 16 (2005), pp. 477-481
[4]
M. Kuwana, J. Kaburaki, Y. Okazaki, H. Miyazaki, Y. Ikeda.
Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus.
Rheumatology, 45 (2006), pp. 851-854
[5]
M. Kuwana, Y. Okazaki, M. Kajihara, J. Kaburaki, H. Miyazaki, Y. Kawakami, et al.
Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia.
Arthritis Rheum, 46 (2002), pp. 2148-2159
[6]
T. Nagasawa, T. Sakurai, H. Kashiwagi, T. Abe.
Cell-mediated amegakaryocytic thrombocytopenia associated with systemic lupus erythematosus.
Blood, 67 (1986), pp. 479-483
[7]
P.F. Griner, L.W. Hoyer.
Amegakaryocytic thrombocytopenia in systemic lupus erythematosus.
Arch Intern Med, 125 (1970), pp. 328-332
[8]
E. Chalayer, N. Costedoat-Chalumeau, O. Beyne-Rauzy, J. Ninet, S. Durupt, J. Tebib, et al.
Bone marrow involvement in systemic lupus erythematosus.
[9]
R.M. Pereira, E.R. Velloso, Y. Menezes, S. Gualandro, J. Vassalo, N.H. Yoshinari.
Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias.
Clin Rheumatol, 17 (1998), pp. 219-222
[10]
H. Chang, T.C. Tang.
Successful treatment of amegakaryocytic thrombocytopenia with azathioprine.
Acta Haematol, 126 (2011), pp. 135-137
Copyright © 2018. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?